<Anchor> The
AstraZeneca and Pfizer vaccines that have just appeared are directly related to us.
As a result, concerns have arisen whether we are also affected, but the government has stated that the supply plan has not changed so far.
Reporter Jang Se-man continues.
<Reporter> The
vaccine that the government said it would bring to Korea in the first quarter of this year is the quantity through Cobax Facility, a vaccine joint purchase organization with AstraZeneca.
Of these, 50,000 initial shipments through Kovacs are expected to be the first to enter Korea early next month, and the government is explaining that Pfizer vaccine is the most powerful.
Daum is planning to supply 750,000 AstraZeneca vaccines produced in Korea in mid-February, and the remaining 9.25 million in the first quarter.
20 million people from Modena and 6 million Janssen are scheduled for the second quarter, and 10 million Pfizer are scheduled for the third quarter.
The question is whether or not the first shipments expected at the beginning of next month are abnormal.
The quarantine authorities have so far not been contacted by vaccine producers about a supply disruption, and drew a line that there would be no problems with the supply plan.
In particular, the AstraZeneca vaccine is supplied by SK Bioscience's consignment production in Korea, so there will be no disruption in supply in the first quarter.
[Son Young-rae / Head of Social Strategy Division, Central Accident Control Headquarters: Until now, we have not received any notification that there is a separate setback in vaccine supply.
Therefore, it is determined that it will be supplied on schedule until now...
.]
Specific vaccine availability and vaccination schedules will be announced this Thursday.
(Video coverage: Jeong Seong-hwa, video editing: Kim Ho-jin)